Psoriasis Clinical Trials in Phoenix

Showing 121-140 of 181 trials

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

Moderate and Severe Active Rheumatoid ArthritisActive Psoriatic ArthritisActive Ankylosing Spondylitis+1 more

UCB Biopharma S.P.R.L.70 participantsStarted Nov 2017

Mesa, Arizona, United States • Mesa, Arizona, United States • Phoenix, Arizona, United States +19 more locations

COMPLETEDPhase 3< 1 mile

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.

PsoriasisPlaque Psoriasis

UCB Biopharma S.P.R.L.227 participantsStarted Dec 2014

Phoenix, Arizona, United States • Bakersfield, California, United States • Santa Monica, California, United States +20 more locations

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Psoriasis Trials in Other Cities

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

A Study of Ixekizumab in Participants With Plaque Psoriasis

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

A Study in Participants With Moderate to Severe Psoriasis

Vascular Inflammation in Psoriasis - Extension Study

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Other Conditions in Phoenix